Recruiting
Acquired C1 inhibitor deficiency
RecruitingStudy to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema
Investigational
Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema
Investigational
- Disease:Acquired C1 inhibitor deficiency
- Substances:Deucrictibant
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Deucrictibant
- Sponsor:Pharvaris Netherlands B.V.




